Skip to main content
SpringerLink
Log in

Alendronate versus alfacalcidol in the prevention of glucocorticoid-induced bone loss

  • Practice Point
  • Published:

From Nature Clinical Practice Rheumatology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Richy F et al. (2005) Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis. Calcif Tissue Int 76: 176–186

    Article  CAS  Google Scholar 

  2. Lucky MM et al.(2003) Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis. Obstet Gynecol 101: 711–721

    Google Scholar 

  3. Hahn, TJ et al. (1979) Altered mineral metabolism in glucocorticoid-induced osteopenia. Effect of 25 hydroxy vitamin D administration. J Clin Invest 63: 655–663

    Article  Google Scholar 

  4. Holick MF (2006) The role of vitamin D in bone health and fracture prevention. Curr Osteoporosis Rep 4: 96–102

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Jasmine Farsarakis, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Bevra H Hahn is a Professor of Medicine and the Chief of Rheumatology, and TJ Hahn is a Professor of Medicine, at the David Geffen School of Medicine at the University of California in Los Angeles. TJ Hahn is also Chief of Geriatrics, at the West Los Angeles Veteran's Administration Health Care Center, CA, USA.,

    Bevra H Hahn & Theodore J Hahn

Authors
  1. Bevra H Hahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Theodore J Hahn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bevra H Hahn.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hahn, B., Hahn, T. Alendronate versus alfacalcidol in the prevention of glucocorticoid-induced bone loss. Nat Rev Rheumatol 3, 10–11 (2007). https://doi.org/10.1038/ncprheum0370

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncprheum0370

  • Springer Nature Limited

Search

Navigation